Ramucirumab (IMC-1121B ) + Paclitaxel
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adenocarcinoma
Conditions
Adenocarcinoma
Trial Timeline
Nov 1, 2010 → Oct 1, 2011
NCT ID
NCT01253525About Ramucirumab (IMC-1121B ) + Paclitaxel
Ramucirumab (IMC-1121B ) + Paclitaxel is a phase 1 stage product being developed by Eli Lilly for Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01253525. Target conditions include Adenocarcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01253525 | Phase 1 | Completed |
Competing Products
20 competing products in Adenocarcinoma